65 results
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Survival #EBM #Honc ... #Osimertinib #NSCLC ... #Survival #NEJM
Differential Diagnosis of Anemias #Diagnosis #IM #Honc #Anemia #Differential #Iron #Algorithm #Microcytic #Macrocytic #Normocytic #Ddxof
Anemias #Diagnosis #IM ... #Honc #Anemia #
Algorithm for the Evaluation of Anemia #Diagnosis #EM #IM #Honc #Anemia #Differential #Workup #Algorithm #Microcytic #Macrocytic
Diagnosis #EM #IM ... #Honc #Anemia #
Evaluation of Lymphadenopathy - Localized vs Generalized #Diagnosis #EM #IM #Honc #Lymphadenopathy #Localized #Generalized #Infectious #Malignancy
Diagnosis #EM #IM ... #Honc #Lymphadenopathy
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Lung Cancer #EBM #Honc ... #ALKPositive #NSCLC ... VisualAbstract #NEJM
Early Events in Acute GVHD #Pathophys #Honc #GVHD #GraftVersusHostDisease #NEJM
GVHD #Pathophys #Honc ... GraftVersusHostDisease #NEJM
Possible Mechanisms Underlying Immune-Related Adverse Events #Pathophys #Honc #ImmuneRelatedAdverseEvents #Immunotherapy #NEJM
Events #Pathophys #Honc ... Immunotherapy #NEJM
The Pathway of Heme Synthesis, Showing Pathway Intermediates and End-Product Regulation by Heme #Pathophys #Honc #Heme
Heme #Pathophys #Honc ... Synthesis #Porphyria #NEJM
Biologic Events Leading to Chronic GVHD #Pathophys #Honc #Pharm #GVHD #GraftVersusHostDisease #Therapeutic #Pathways #NEJM
GVHD #Pathophys #Honc ... Therapeutic #Pathways #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
#EBM #Honc #PACIFIC ... #Durvalumab #NSCLC ... #NEJM